Moreover, the low expression or deletion of MEG3 was associated with advanced tumor node metastasis stage and poor prognosis in non-small-cell lung cancer (NSCLC) [29], colorectal cancer [30], gastric cancer [31], and cervical cancer [32]. This evidence concerns the gene MEG3 and non-small cell lung carcinoma.